Sector News

Amgen appoints Wanda M. Austin to board Of directors

October 25, 2017
Life sciences

Amgen has announced the appointment of Wanda M. Austin to its Board of Directors, effective upon the December Board and committee meetings.

Dr. Austin will serve as a member of the Board’s Audit Committee and the Corporate Responsibility and Compliance Committee. Following the appointment of Dr. Austin, the Board will comprise 14 directors, 13 of whom are independent.

“We are pleased to welcome Dr. Wanda Austin to Amgen’s Board,” said Robert A. Bradway, chairman and chief executive officer of Amgen.  “Wanda’s deep experience in long-cycle technology and engineering settings and her senior leadership experience will be invaluable to Amgen.”

Dr. Austin, 63, is the retired president and chief executive officer of The Aerospace Corporation, a leading architect of the United States’ national security space programs, where she served from 2008 until her retirement in 2016.  From 2004 to 2007, Dr. Austin was senior vice president, National Systems Group of The Aerospace Corporation.  Dr. Austin joined The Aerospace Corporation in 1979 and served in various positions from 1979 until 2004.

Dr. Austin has served as an Adjunct Research Professor at the University of Southern California’s Viterbi School of Engineering since 2007.  She is the co-founder of MakingSpace, where she serves as a motivational speaker on STEM education.

Dr. Austin has been a director of Chevron Corporation, a petroleum, exploration, production and refining company, since 2016.  She is a trustee of the University of Southern California and previously served on the boards of directors of the National Geographic Society and the Space Foundation.

Dr. Austin received an undergraduate degree from Franklin & Marshall College, a master’s degree from the University of Pittsburgh and a doctorate from the University of Southern California.

Source: Amgen

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).